DK1543013T3 - 5-[[(2,3-Diflourphenyl)methyl]-7-[[2-hydroxymethyl)-1-methylethyl]amino]thiazolo(4,5-d]pyrimidin-2(3H)-on, mononatriumsalt som CXCR2-antagonist - Google Patents

5-[[(2,3-Diflourphenyl)methyl]-7-[[2-hydroxymethyl)-1-methylethyl]amino]thiazolo(4,5-d]pyrimidin-2(3H)-on, mononatriumsalt som CXCR2-antagonist

Info

Publication number
DK1543013T3
DK1543013T3 DK03748263T DK03748263T DK1543013T3 DK 1543013 T3 DK1543013 T3 DK 1543013T3 DK 03748263 T DK03748263 T DK 03748263T DK 03748263 T DK03748263 T DK 03748263T DK 1543013 T3 DK1543013 T3 DK 1543013T3
Authority
DK
Denmark
Prior art keywords
diflourphenyl
cxcr2
thiazolo
pyrimidin
methylethyl
Prior art date
Application number
DK03748263T
Other languages
English (en)
Inventor
Roger Victor Bonnert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1543013T3 publication Critical patent/DK1543013T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03748263T 2002-09-20 2003-09-16 5-[[(2,3-Diflourphenyl)methyl]-7-[[2-hydroxymethyl)-1-methylethyl]amino]thiazolo(4,5-d]pyrimidin-2(3H)-on, mononatriumsalt som CXCR2-antagonist DK1543013T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221828.7A GB0221828D0 (en) 2002-09-20 2002-09-20 Novel compound
PCT/GB2003/003998 WO2004026880A1 (en) 2002-09-20 2003-09-16 Novel compound

Publications (1)

Publication Number Publication Date
DK1543013T3 true DK1543013T3 (da) 2009-03-09

Family

ID=9944428

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03748263T DK1543013T3 (da) 2002-09-20 2003-09-16 5-[[(2,3-Diflourphenyl)methyl]-7-[[2-hydroxymethyl)-1-methylethyl]amino]thiazolo(4,5-d]pyrimidin-2(3H)-on, mononatriumsalt som CXCR2-antagonist

Country Status (27)

Country Link
US (2) US7585867B2 (da)
EP (1) EP1543013B1 (da)
JP (1) JP4619787B2 (da)
KR (1) KR20050057427A (da)
CN (1) CN1315848C (da)
AR (1) AR041340A1 (da)
AT (1) ATE419254T1 (da)
AU (1) AU2003267571B2 (da)
BR (1) BR0314844A (da)
CA (1) CA2498762A1 (da)
DE (1) DE60325614D1 (da)
DK (1) DK1543013T3 (da)
ES (1) ES2318152T3 (da)
GB (1) GB0221828D0 (da)
HK (1) HK1077060A1 (da)
IS (1) IS7793A (da)
MX (1) MXPA05002935A (da)
NO (1) NO20051892L (da)
NZ (1) NZ538826A (da)
PL (1) PL375952A1 (da)
PT (1) PT1543013E (da)
RU (1) RU2342389C2 (da)
SI (1) SI1543013T1 (da)
TW (1) TW200413395A (da)
UA (1) UA81257C2 (da)
WO (1) WO2004026880A1 (da)
ZA (1) ZA200502272B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
CN101277689B (zh) * 2005-08-08 2011-01-12 詹森药业有限公司 噻唑并嘧啶类激酶抑制剂
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924472A (en) * 1957-06-27 1960-02-09 Gen Motors Corp Pipe joint seal
GB1009477A (en) 1962-02-13 1965-11-10 Smith Kline French Lab Novel process for preparing heterocyclic compounds
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
BE668603A (da) * 1964-08-20
DE2331223C2 (de) 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4120521A (en) * 1975-08-28 1978-10-17 Rieber & Son Plastic-Industri A/S Combined mould element and sealing ring
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
GB1600293A (en) * 1977-02-04 1981-10-14 British Oceanics Ltd Sealing arrangements
US4188040A (en) * 1977-04-06 1980-02-12 Firma WOCO Franz-Josef Wolf & Co. Sealing ring
DE2726959A1 (de) * 1977-06-15 1979-01-18 Arlt Christian Dichteinsatz zum dichten verbinden von zwei rohren
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
US4410528A (en) * 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
DE3219522A1 (de) * 1981-10-28 1983-12-01 Denso-Chemie Wedekind Kg, 5090 Leverkusen Steckmuffendichtung fuer rohre
FR2547888B1 (fr) * 1983-06-22 1985-12-13 Sabla Sa Bague d'etancheite a implants pour tuyaux a emboitement
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
SE8800348L (sv) * 1988-02-03 1989-08-04 Forsheda Ab Taetningsring och verktyg foer framstaellning daerav
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
DE4119767A1 (de) 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5169161A (en) * 1991-09-19 1992-12-08 Hail Mary Rubber Co., Inc. Symmetrical gasket for pipe joints
DE4134089C2 (de) * 1991-10-15 1994-10-13 Dueker Eisenwerk Schubgesicherte Muffenverbindung
JPH05188994A (ja) 1992-01-07 1993-07-30 Sony Corp 騒音抑圧装置
DE4229609C2 (de) * 1992-09-04 2003-05-08 Forsheda Stefa Gmbh Abdichtung zwischen zwei ineinandersteckbaren Teilen
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SE515033C2 (sv) * 1995-12-27 2001-06-05 Forsheda Ab Tätningsanordning
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
EP0898568B1 (en) 1996-04-19 2006-10-04 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
AU735401B2 (en) 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
NZ504800A (en) * 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
DK1049689T3 (da) 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
EP1070715A4 (en) * 1998-03-19 2002-10-17 Nihon Nohyaku Co Ltd ARYLPIPERIDINE AND THEIR USE
JP2002510695A (ja) 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US5988695A (en) * 1998-08-26 1999-11-23 S&B Technical Products, Inc. Pipe gasket with embedded ring
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
AU770551B2 (en) 1998-12-28 2004-02-26 4-Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000045800A2 (en) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6142484A (en) * 1999-04-15 2000-11-07 Vassallo Research & Development Corporation Composite multi-pressure gasket
AU5600100A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US7169778B2 (en) * 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ATE306488T1 (de) 2000-01-05 2005-10-15 Pfizer Benzimidazol-verbindungen zur verwendung als orl1-rezeptor-antagonisten
AU2001232556A1 (en) 2000-02-11 2001-08-20 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359079A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
US6790854B2 (en) * 2000-03-24 2004-09-14 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid receptor agonists
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
WO2006064228A2 (en) 2004-12-17 2006-06-22 Astrazeneca Ab Thiazolopyramidine compounds for the modulation of chemokine receptor activity

Also Published As

Publication number Publication date
PT1543013E (pt) 2009-02-27
JP4619787B2 (ja) 2011-01-26
HK1077060A1 (en) 2006-02-03
US20080306262A1 (en) 2008-12-11
KR20050057427A (ko) 2005-06-16
US7585867B2 (en) 2009-09-08
CN1315848C (zh) 2007-05-16
AU2003267571A1 (en) 2004-04-08
GB0221828D0 (en) 2002-10-30
AU2003267571B2 (en) 2007-08-16
EP1543013B1 (en) 2008-12-31
NZ538826A (en) 2006-12-22
SI1543013T1 (sl) 2009-04-30
EP1543013A1 (en) 2005-06-22
AR041340A1 (es) 2005-05-11
IS7793A (is) 2005-04-11
RU2005106356A (ru) 2005-11-20
NO20051892L (no) 2005-06-17
US20060100221A1 (en) 2006-05-11
ATE419254T1 (de) 2009-01-15
WO2004026880A1 (en) 2004-04-01
ES2318152T3 (es) 2009-05-01
JP2006503835A (ja) 2006-02-02
CN1681826A (zh) 2005-10-12
MXPA05002935A (es) 2005-05-27
RU2342389C2 (ru) 2008-12-27
CA2498762A1 (en) 2004-04-01
ZA200502272B (en) 2005-09-19
DE60325614D1 (de) 2009-02-12
UA81257C2 (en) 2007-12-25
BR0314844A (pt) 2005-08-09
TW200413395A (en) 2004-08-01
PL375952A1 (en) 2005-12-12

Similar Documents

Publication Publication Date Title
DK1543013T3 (da) 5-[[(2,3-Diflourphenyl)methyl]-7-[[2-hydroxymethyl)-1-methylethyl]amino]thiazolo(4,5-d]pyrimidin-2(3H)-on, mononatriumsalt som CXCR2-antagonist
DE60318888D1 (de) Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK0996621T3 (da) Triazolo[4,5-d]pyrimidin-derivater som anti-trombotiske midler
DE69915675D1 (de) Triazolo[4,5-d]pyrimidin-derivate
HK1118556A1 (en) 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
DE60311101D1 (de) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido und 2,3-dihydro-2h-pyrrolo (2,1-b)-chinazolinon-derivate
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
HK1091495A1 (en) Pyrimidin-5(1h)-one derivatives
DK1689751T3 (da) 5,7-diaminpyrazolo[4,3-D]pyrimidiner med PDE-5-inhiberende aktivitet
NO20030033D0 (no) Pyrido[2,3-D]pyrimidin- og pyrimido[4,5-D]pyrimidin- nukleosider
IL185913A0 (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives
IS7323A (is) 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
DE60016615D1 (de) Pyrazolo[4,3-d]pyrimidinderivate
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
MA26829A1 (fr) Derives de purines
IL180757A0 (en) Imidazo[4,5-d] pyrimidines, their uses and methods of preparation
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DK1497294T3 (da) 1,2,3,4,7,8-Hexahydro-6H[1,4]diazepino[6,7,1-ij]guinolinderivater som antipsykotiske midler og midler med adiposistas
DK1430057T3 (da) Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
AU2001250376A1 (en) Dihydroimidazo(2,1-b)thiazole and dihydro-5h-thiazolo(3,2-a)pyrimidines as antidepressant agents
DK1218380T3 (da) Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
DE60308836D1 (de) Ophthalmische zubereitung mit ascomycin